ANGELA ANUKAM: Open Payments
NPI 1841734944 · NEW YORK, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,537 in 66 payments from 9 companies in 2025. Trend: 2023 $2,047 · 2024 $2,084 · 2025 $2,537
Food & beverage: $2,433Education: $104
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 28 | $1,040 |
| ABBVIE INC. | 24 | $507 |
| Teva Pharmaceuticals USA, Inc. | 4 | $255 |
| Otsuka America Pharmaceutical, Inc. | 3 | $221 |
| Gilead Sciences, Inc. | 2 | $154 |
| Neurocrine BioSciences, Inc. | 1 | $129 |
| E.R. Squibb & Sons, L.L.C. | 1 | $125 |
| Alkermes, Inc. | 1 | $76 |
| Vanda Pharmaceuticals Inc. | 2 | $31 |
Products named: CAPLYTA, VRAYLAR, AUSTEDO XR, INGREZZA, COBENFY, ABILIFY MAINTENA, Epclusa, REXULTI.
Industry payments across NY — which companies pay providers there.
